IMIST


Gene therapy of cancer : (notice n° 7780)

000 -LEADER
fixed length control field 05321cam a2200421' 4500
001 - CONTROL NUMBER
control field UNI0001601
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20161123112308.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 140806s2002 us a b 001 eng
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9780124375512
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 0124375510
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9780080491363 (electronic bk.)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 0080491367 (electronic bk.)
040 ## - CATALOGING SOURCE
Modifying agency IMIST
Description conventions rda
040 ## - CATALOGING SOURCE
Original cataloging agency OPELS
Description conventions rda
041 1# - LANGUAGE CODE
Language code of text/sound track or separate title eng
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RC271.G45
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 616.99/4042
245 #0 - TITLE STATEMENT
Title Gene therapy of cancer :
Remainder of title translational approaches from preclinical studies to clinical implementation /
Statement of responsibility, etc edited by Edmund C. Lattime, Stanton L. Gerson.
250 ## - EDITION STATEMENT
Edition statement 2nd ed.
300 ## - PHYSICAL DESCRIPTION
Extent 1 online resource (xix, 534 pages) :
Other physical details illustrations (some color)
500 ## - GENERAL NOTE
General note The Second Edition of Gene Therapy of Cancer provides crucial updates on the basic science and ongoing research in this field, examining the state of the art technology in gene therapy and its therapeutic applications to the treatment of cancer. The clinical chapters are improved to include new areas of research and more successful trials. Chapters emphasize the scientific basis of gene therapy using immune, oncogene, antisense, pro-drug activating, and drug resistance gene targets, while other chapters discuss therapeutic approaches and clinical applications. This book is a valuable reference for anyone needing to stay abreast of the latest advances in gene therapy treatment for cancer. Key Features * Provides in-depth description of targeted systems and treatment strategies * Explains the underlying cancer biology necessary for understanding a given therapeutic approach * Extensively covers immune therapeutics of vaccines, cytokines, and peptide-induced responses * Presents translational focus with emphasis on requirements for clinical implementation * Incorporates detailed illustrations of vectors and therapeutic approaches ideal for classroom presentations and general reference.
504 ## - BIBLIOGRAPHY, ETC. NOTE
Bibliography, etc Includes bibliographical references and index.
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Ch. 1. Retroviral vector design for cancer gene therapy -- Ch. 2. Noninfectious gene transfer and expression systems for cancer gene therapy -- Ch. 3. Parvovirus vectors for the gene therapy of cancer -- Ch. 4. Antibody-targeted gene therapy -- Ch. 5. Ribozymes in cancer gene therapy -- Ch. 6. The advent of lentiviral vectors: prospects for cancer therapy -- Ch. 7. Immunologic targets for the gene therapy of cancer -- Ch. 8. Development of epitope-specific immunotherapies for human malignancies and premalignant lesions expressing mutated ras genes -- Ch. 9. Introduction to dendritic cells -- Ch. 10. DNA and dendritic cell-based genetic immunization against cancer -- Ch. 11. RNA-transfected dendritic cells as immunogens -- Ch. 12. In Situ immune modulation using recombinant vaccinia virus vectors: preclinical studies to clinical implementation -- Ch. 13. The use of particle-mediated gene transfer for immunotherapy of cancer -- Ch. 14. Applications of gene transfer in the adoptive immunotherapy of cancer -- Ch. 15. Update on the use of genetically modified hematopoietic stem cells for cancer therapy -- Ch. 16. Clinical applications of tumor-suppressor gene therapy -- Ch. 17. Cancer gene therapy with tumor suppressor genes involved in cell-cycle control.
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Ch. 18. Cancer gene therapy with the p53 tumor suppressor gene -- Ch. 19. Antisense downregulation of the apoptosis-related Bcl-2 and Bcl-xl proteins: a new approach to cancer therapy -- Ch. 20. Gene therapy for chronic myelogenous leukemia -- Ch. 21. Transfer of drug-resistance genes into hematopoietic progenitors -- Ch. 22. Multidrug-resistance gene therapy in hematopoietic cell transplantation -- Ch. 23. Development and application of an engineered dihydrofolate reductase and cytidine-deaminase-based fusion genes in myeloprotection-based gene therapy strategies -- Ch. 24. Protection from antifolate toxicity by expression of drug-resistant dihydrofolate reductase -- Ch. 25. A genomic approach to the treatment of breast cancer -- Ch. 26. Antiangiogenic gene therapy -- Ch. 27. VEGF-targeted antiangiogenic gene therapy -- Ch. 28. Strategies for combining gene therapy with ionizing radiation to improve antitumor efficacy -- Ch. 29. Virotherapy with replication-selective oncolytic adenoviruses: a novel therapeutic platform for cancer -- Ch. 30. E1A cancer gene therapy -- Ch. 31. Preemptive and therapeutic uses of suicide genes for cancer and leukemia -- Ch. 32. Treatment of mesothelioma using adenoviral-mediated delivery of herpes simplex virus thymidline kinase gene in combination with ganciclovir -- Ch. 33. The use of suicide gene therapy for the treatment of malignancies of the brain -- Ch. 34. Case study of combined gene and radiation therapy as an approach in the treatment of cancer.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Cancer
General subdivision Gene therapy.
-- Immunotherapy.
-- genetics.
-- therapy.
-- methods.
-- methods.
-- Thérapie génique.
-- Immunothérapie.
-- Oncology.
-- Diseases
-- Cancer.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Cancer
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Neoplasms
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Neoplasms
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Gene Therapy
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Immunotherapy
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Protein Biosynthesis
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Cancer
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Cancer
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element MEDICAL
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element HEALTH & FITNESS
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Lattime,, Edmund C.
Dates associated with a name 1951-
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Gerson,, Stanton L.
Exemplaires
Withdrawn status Lost status Damaged status Not for loan Permanent Location Current Location Date acquired Inventory number Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
        La bibliothèque des Sciences Médicales et Pharmaceutiques La bibliothèque des Sciences Médicales et Pharmaceutiques   10652   616.994 LAT 0000000009478 11/23/2016 11/23/2016 Livre
© Tous droits résérvés IMIST/CNRST
Angle Av. Allal Al Fassi et Av. des FAR, Hay Ryad, BP 8027, 10102 Rabat, Maroc
Tél:(+212) 05 37.56.98.00
CNRST / IMIST

Propulsé par Koha